



上海源叶生物科技有限公司
 Shanghai yuanye Bio-Technology Co., Ltd
 电话: 021-61312973 传真: 021-55068248
 网址: www.shyuanye.com
 邮箱: shyysw@sina.com

产品名称: **Cadazolid**
 产品别名: **ACT-179811**

生物活性:																				
Description	Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.																			
In Vitro	Cadazolid is a new antibiotic in development for the treatment of Clostridium difficile-associated diarrhea[1]. Cadazolid is active against all (including linezolid- and moxifloxacin-resistant) Clostridium difficile strains (MIC90 0.125, range 0.03-0.25 mg/L). The cadazolid geometric mean MIC is 152-fold, 16-fold, 9-fold and 7-fold lower than those of moxifloxacin, linezolid, metronidazole and vancomycin, respectively. Both cadazolid dosing regimens rapidly reduce Clostridium difficile viable counts and cytotoxin with no evidence of recurrence. Cadazolid levels persists at 50-100-fold supra-MIC for 14 days post-dosing. Cadazolid inhibition of enumerated gut microflora is limited, with the exception of bifidobacteria; Bacteroides fragilis group and Lactobacillus spp. counts are unaffected. There is no evidence for selection of strains resistant to cadazolid, quinolones or linezolid[2].																			
In Vivo	Cadazolid is well tolerated up to 3000 mg given twice daily for 10 days. The most common adverse event is headache, with no observed relationship between dose or treatment duration and adverse events. Plasma concentrations of cadazolid are low. No plasma concentrations >3.3 ng/mL are observed after single doses or >6.9 ng/mL after 10 days of multiple doses. Food increased the mean Cmax from 0.73 to 1.87 ng/mL and mean AUC0-t from 3.13 to 15.69 ng-h/mL after a single 300 mg dose. The increase in systemic exposure to cadazolid across doses is less than dose-proportional. The mean cumulative faecal recovery is 81.0%-93.5%. Urinary recovery of unchanged compound is less than 0.015%[1].																			
Solvent&Solubility	<p>In Vitro: DMSO : ≥ 150 mg/mL (256.17 mM) * "≥" means soluble, but saturation unknown.</p>																			
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing</th> <th>Solvent Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Stock Solutions</td> <td>1 mM</td> <td>1.7078 mL</td> <td>8.5390 mL</td> <td>17.0780 mL</td> </tr> <tr> <td>5 mM</td> <td>0.3416 mL</td> <td>1.7078 mL</td> <td>3.4156 mL</td> </tr> <tr> <td>10 mM</td> <td>0.1708 mL</td> <td>0.8539 mL</td> <td>1.7078 mL</td> </tr> </tbody> </table>	Preparing	Solvent Mass	1 mg	5 mg	10 mg	Concentration	Stock Solutions	1 mM	1.7078 mL	8.5390 mL	17.0780 mL	5 mM	0.3416 mL	1.7078 mL	3.4156 mL	10 mM	0.1708 mL	0.8539 mL	1.7078 mL
	Preparing		Solvent Mass				1 mg		5 mg	10 mg										
		Concentration																		
Stock Solutions	1 mM	1.7078 mL	8.5390 mL	17.0780 mL																
	5 mM	0.3416 mL	1.7078 mL	3.4156 mL																
	10 mM	0.1708 mL	0.8539 mL	1.7078 mL																
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p>																				
References	<p>[1]. Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014 Mar;69(3):706-14.</p> <p>[2]. Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69(3):697-705.</p>																			
实验参考:																				
	MICs of cadazolid, metronidazole, vancomycin, moxifloxacin and linezolid are determined using																			



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

Cell Assay	agar incorporation for 100 Clostridium difficile isolates, including 30 epidemic strains (ribotypes 027, 106 and 001) with reduced metronidazole susceptibility, 2 linezolid-resistant isolates and 2 moxifloxacin-resistant isolates. The efficacy of two cadazolid dosing regimens (250 versus 750 mg/L twice daily for 7 days) to treat simulated CDI is evaluated. Microflora populations, Clostridium difficile total viable counts and spores, cytotoxin titres, possible emergence of cadazolid, linezolid or quinolone resistance, and antimicrobial concentrations are monitored throughout[2].
References	[1]. Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014 Mar;69(3):706-14. [2]. Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69(3):697-705.



源叶生物